Title | Integration of Hedgehog and mutant FLT3 signaling in myeloid leukemia. |
Publication Type | Journal Article |
Year of Publication | 2015 |
Authors | Lim Y, Gondek L, Li L, Wang Q, Ma H, Ma H, Chang E, Huso DL, Foerster S, Marchionni L, McGovern K, Watkins DNeil, Peacock CD, Levis M, Smith BDouglas, Merchant AA, Small D, Matsui W |
Journal | Sci Transl Med |
Volume | 7 |
Issue | 291 |
Pagination | 291ra96 |
Date Published | 2015 Jun 10 |
ISSN | 1946-6242 |
Keywords | Animals, Cell Compartmentation, Cell Line, Tumor, Cell Proliferation, Cell Survival, Disease Progression, Drug Synergism, fms-Like Tyrosine Kinase 3, Gene Duplication, Hedgehog Proteins, Humans, Kruppel-Like Transcription Factors, Leukemia, Myeloid, Acute, Mice, Mutant Proteins, Myeloproliferative Disorders, Niacinamide, Nuclear Proteins, Phenylurea Compounds, Receptors, G-Protein-Coupled, Signal Transduction, Smoothened Receptor, Sorafenib, STAT5 Transcription Factor, Stem Cells, Veratrum Alkaloids, Zinc Finger Protein Gli2 |
Abstract | FMS-like tyrosine kinase 3 (FLT3) internal tandem duplication (ITD) mutations resulting in constitutive kinase activity are common in acute myeloid leukemia (AML) and carry a poor prognosis. Several agents targeting FLT3 have been developed, but their limited clinical activity suggests that the inhibition of other factors contributing to the malignant phenotype is required. We examined gene expression data sets as well as primary specimens and found that the expression of GLI2, a major effector of the Hedgehog (Hh) signaling pathway, was increased in FLT3-ITD compared to wild-type FLT3 AML. To examine the functional role of the Hh pathway, we studied mice in which Flt3-ITD expression results in an indolent myeloproliferative state and found that constitutive Hh signaling accelerated the development of AML by enhancing signal transducer and activator of transcription 5 (STAT5) signaling and the proliferation of bone marrow myeloid progenitors. Furthermore, combined FLT3 and Hh pathway inhibition limited leukemic growth in vitro and in vivo, and this approach may serve as a therapeutic strategy for FLT3-ITD AML. |
DOI | 10.1126/scitranslmed.aaa5731 |
Alternate Journal | Sci Transl Med |
PubMed ID | 26062848 |
PubMed Central ID | PMC4644635 |
Grant List | R01 CA090668 / CA / NCI NIH HHS / United States R21CA155733 / CA / NCI NIH HHS / United States P30 DK090868 / DK / NIDDK NIH HHS / United States R01 CA150142 / CA / NCI NIH HHS / United States UL1 TR001079 / TR / NCATS NIH HHS / United States P30CA006973 / CA / NCI NIH HHS / United States P30 CA006973 / CA / NCI NIH HHS / United States R01 CA127574 / CA / NCI NIH HHS / United States T32 HL007525 / HL / NHLBI NIH HHS / United States P30DK090868 / DK / NIDDK NIH HHS / United States R21 CA155733 / CA / NCI NIH HHS / United States R01CA127574 / CA / NCI NIH HHS / United States K08 CA154975 / CA / NCI NIH HHS / United States R01 CA174951 / CA / NCI NIH HHS / United States R01CA174951 / CA / NCI NIH HHS / United States R01CA090668 / CA / NCI NIH HHS / United States UL1TR001079 / TR / NCATS NIH HHS / United States |
Related Faculty:
Luigi Marchionni, M.D., Ph.D.